What’s Ahead for Fibrocell Science Inc (FCSC) After Today’s Huge Increase?

September 17, 2017 - By Winifred Garcia

Investors sentiment decreased to 0.47 in 2016 Q4. Its down 0.03, from 0.5 in 2016Q3. It dived, as 8 investors sold Fibrocell Science Inc shares while 9 reduced holdings. 2 funds opened positions while 6 raised stakes. 23.97 million shares or 3.70% less from 24.89 million shares in 2016Q3 were reported.
Northern Trust Corporation owns 39,087 shares. Blackrock Invest Llc owns 4,521 shares for 0% of their portfolio. Franklin Street Advsr Nc holds 0.01% of its portfolio in Fibrocell Science Inc (NASDAQ:FCSC) for 50,000 shares. Bnp Paribas Arbitrage invested 0% in Fibrocell Science Inc (NASDAQ:FCSC). Morgan Stanley owns 25,281 shares. Fmr Limited Liability accumulated 0% or 2.61M shares. Renaissance Llc stated it has 194,000 shares or 0% of all its holdings. State Street reported 11,300 shares. Vanguard Group Incorporated reported 1.17 million shares. Bankshares Of Ny Mellon invested 0% in Fibrocell Science Inc (NASDAQ:FCSC). Wells Fargo Mn stated it has 0% of its portfolio in Fibrocell Science Inc (NASDAQ:FCSC). Moreover, Third Security Ltd Company has 0.56% invested in Fibrocell Science Inc (NASDAQ:FCSC) for 16.62 million shares. Janney Montgomery Scott Ltd Limited Liability Company holds 0% or 11,000 shares. Health Value Capital Lc has invested 0.03% of its portfolio in Fibrocell Science Inc (NASDAQ:FCSC). Cambridge Investment Rech Advsrs has invested 0% in Fibrocell Science Inc (NASDAQ:FCSC).

The stock of Fibrocell Science Inc (NASDAQ:FCSC) is a huge mover today! The stock increased 5.96% or $0.19 on September 15, reaching $3.38. About 114,100 shares traded or 61.32% up from the average. Fibrocell Science Inc (NASDAQ:FCSC) has declined 57.80% since September 17, 2016 and is downtrending. It has underperformed by 74.50% the S&P500.
The move comes after 7 months positive chart setup for the $49.74M company. It was reported on Sep, 17 by Barchart.com. We have $3.58 PT which if reached, will make NASDAQ:FCSC worth $2.98 million more.

Investors wait Fibrocell Science Inc (NASDAQ:FCSC) to report on November, 2. its quarterly earnings Wall Street analysts expect $-0.41 earnings per share, down $0.05 or 13.89 % from last year’s $-0.36 same quarter earnings. Fibrocell Science Inc’s Wall Street analysts see 32.26 % negative EPS growth, taking into account the $-0.31 EPS reproted in the previous quarter,

Fibrocell Science Inc (NASDAQ:FCSC) Ratings Coverage

Among 6 analysts covering Fibrocell Science (NASDAQ:FCSC), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Fibrocell Science had 7 analyst reports since September 28, 2015 according to SRatingsIntel. H.C. Wainwright maintained the stock with “Buy” rating in Friday, June 9 report. Roth Capital initiated Fibrocell Science Inc (NASDAQ:FCSC) rating on Tuesday, December 22. Roth Capital has “Buy” rating and $14 target. H.C. Wainwright maintained it with “Buy” rating and $5.7000 target in Wednesday, August 9 report. The firm has “Neutral” rating given on Monday, September 28 by Wedbush. The firm has “Buy” rating given on Tuesday, December 22 by TH Capital.

More notable recent Fibrocell Science Inc (NASDAQ:FCSC) news were published by: Globenewswire.com which released: “Fibrocell Science Appoints Keith A. Goldan, Senior Vice President and Chief …” on March 18, 2015, also Seekingalpha.com with their article: “Fibrocell Science’s (FCSC) CEO John Maslowski on Q2 2017 Results – Earnings …” published on August 11, 2017, Globenewswire.com published: “Fibrocell Reports 2016 Financial Results and Recent Operational Highlights” on March 09, 2017. More interesting news about Fibrocell Science Inc (NASDAQ:FCSC) were released by: Globenewswire.com and their article: “Fibrocell Announces Leadership Changes” published on December 19, 2016 as well as Zacks.com‘s news article titled: “Fibrocell Science (FCSC) Looks Good: Stock Moves Up 13.9% June 20, 2017” with publication date: June 20, 2017.

Fibrocell Science, Inc. is an autologous cell and gene therapy company. The company has market cap of $49.74 million. The Firm is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. It currently has negative earnings. The Company’s product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.